| Addressing overtreatment of screen detected DCIS; the LORIS trial A Francis, J Thomas, L Fallowfield, M Wallis, JMS Bartlett, C Brookes, ... European journal of cancer 51 (16), 2296-2303, 2015 | 355 | 2015 |
| The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers PJ Johnson, SJ Pirrie, TF Cox, S Berhane, M Teng, D Palmer, J Morse, ... Cancer Epidemiology, Biomarkers & Prevention 23 (1), 144-153, 2014 | 290 | 2014 |
| Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More?(aTTom) trial JMS Bartlett, DC Sgroi, K Treuner, Y Zhang, I Ahmed, T Piper, R Salunga, ... Annals of Oncology 30 (11), 1776-1783, 2019 | 159 | 2019 |
| Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both: the … ND James, SJ Pirrie, AM Pope, D Barton, L Andronis, I Goranitis, S Collins, ... JAMA oncology 2 (4), 493-499, 2016 | 82 | 2016 |
| Examining the immunological effects of COVID-19 vaccination in patients with conditions potentially leading to diminished immune response capacity–the OCTAVE trial P Kearns, S Siebert, C Gaskell, A Kirkham, S Pirrie, S Bowden, ... | 73 | 2021 |
| Urinary EpCAM in urothelial bladder cancer patients: characterisation and evaluation of biomarker potential RT Bryan, NJ Shimwell, W Wei, AJ Devall, SJ Pirrie, ND James, ... British journal of cancer 110 (3), 679-685, 2014 | 53 | 2014 |
| Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAM RT Bryan, HL Regan, SJ Pirrie, AJ Devall, KK Cheng, MP Zeegers, ... British journal of cancer 112 (6), 1052-1058, 2015 | 47 | 2015 |
| Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23‐gene panel with utility for non‐invasive diagnosis and risk stratification DG Ward, NS Gordon, RH Boucher, SJ Pirrie, L Baxter, S Ott, L Silcock, ... BJU international 124 (3), 532-544, 2019 | 46 | 2019 |
| SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease E Barnes, CS Goodyear, M Willicombe, C Gaskell, S Siebert, T I de Silva, ... Nature Medicine 29 (7), 1760-1774, 2023 | 44 | 2023 |
| Comparing an imaging-guided pathway with the standard pathway for staging muscle-invasive bladder cancer: preliminary data from the BladderPath study RT Bryan, W Liu, SJ Pirrie, R Amir, J Gallagher, AI Hughes, KP Jefferson, ... European urology 80 (1), 12-15, 2021 | 42 | 2021 |
| Sarcomatoid renal cell carcinoma: clinical outcome and survival after treatment with sunitinib V Kunene, M Miscoria, S Pirrie, MR Islam, M Afshar, E Porfiri Clinical Genitourinary Cancer 12 (4), 251-255, 2014 | 42 | 2014 |
| Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 … ND James, S Pirrie, D Barton, JE Brown, L Billingham, SI Collins, ... Journal of Clinical Oncology 31 (15_suppl), LBA5000-LBA5000, 2013 | 35 | 2013 |
| TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony … N James, S Pirrie, A Pope, D Barton, L Andronis, I Goranitis, S Collins, ... NIHR Journals Library, 2016 | 32 | 2016 |
| Overall survival in men with bone metastases from castration-resistant prostate cancer treated with bone-targeting radioisotopes: a meta-analysis of individual patient data … S Terrisse, E Karamouza, CC Parker, AO Sartor, ND James, S Pirrie, ... JAMA oncology 6 (2), 206-216, 2020 | 31 | 2020 |
| The association between smoking cessation before and after diagnosis and non-muscle-invasive bladder cancer recurrence: a prospective cohort study FHM van Osch, SHJ Jochems, RC Reulen, SJ Pirrie, D Nekeman, ... Cancer Causes & Control 29, 675-683, 2018 | 29 | 2018 |
| Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response‐adapted design in the first‐line treatment of patients with classical … A Gibb, SJ Pirrie, K Linton, V Warbey, K Paterson, AJ Davies, GP Collins, ... British Journal of Haematology 193 (1), 63-71, 2021 | 22 | 2021 |
| Breast cancer index is a predictive biomarker of treatment benefit and outcome from extended tamoxifen therapy: final analysis of the trans-aTTom study JMS Bartlett, DC Sgroi, K Treuner, Y Zhang, T Piper, RC Salunga, ... Clinical Cancer Research 28 (9), 1871-1880, 2022 | 19 | 2022 |
| Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer S Chrysostomou, R Roy, F Prischi, L Thamlikitkul, KL Chapman, U Mufti, ... Science translational medicine 13 (602), eaba4627, 2021 | 19 | 2021 |
| A study of angiogenesis markers in patients with renal cell carcinoma undergoing therapy with sunitinib C Stubbs, AD Bardoli, M Afshar, S Pirrie, M Miscoria, I Wheeley, E Porfiri Anticancer research 37 (1), 253-259, 2017 | 17 | 2017 |
| Predictive factors for response to abiraterone in metastatic castration refractory prostate cancer M Afshar, F Al-Alloosh, S Pirrie, C Rowan, ND James, E Porfiri Anticancer research 35 (2), 1057-1063, 2015 | 16 | 2015 |
Nicholas JamesProfessor of Prostate and Bladder Cancer Research, Institute of Cancer Researchכתובת אימייל מאומתת בדומיין icr.ac.uk
